Ezetimibe (Ezetrol, Zetia)

Ezetimibe (brand names Ezetrol and Zetia) is a selective cholesterol absorption inhibitor. Instead of throttling the body's own cholesterol production the way statins do, ezetimibe blocks the uptake of cholesterol from the gut. That is an entirely separate point of attack, which is why both routes combine without overlap.

Within the lipid modulator group ezetimibe is the mildest tool: no muscle compartment involved, no meaningful metabolism via CYP enzymes, a very flat effect profile. That is exactly what makes it interesting in a research context when a protocol has shifted the lipid picture in an unfavorable direction.

This information is for research and educational purposes only. No medical advice.

The target is Niemann-Pick C1-Like 1 protein, NPC1L1 for short. It is a sterol transporter sitting at the brush border of the small intestinal cells that shuttles cholesterol inward. Altmann and colleagues identified this protein in Science in 2004 as the decisive channel. Garcia-Calvo and colleagues showed directly in PNAS a year later that this exact transporter is the binding site of ezetimibe.

Two things get blocked: cholesterol from food and cholesterol returned to the gut via bile. The second share is the larger one. The liver therefore receives less cholesterol and responds by upregulating its LDL receptors, which pulls more LDL out of the blood.

• Point of attack: the intestinal enterocyte, not hepatic synthesis.
• Consequence: upregulation of hepatic LDL receptors.
• Combinability: independent of the statin mechanism, therefore additive.

Ezetimibe is a pharmacokinetic special case. After intake the compound is absorbed rapidly and almost completely converted in the intestinal wall and the liver into ezetimibe glucuronide. Unlike the usual pattern this metabolite is not inactive but active itself. It is transported back specifically to the brush border.

Via enterohepatic recirculation the substance therefore shuttles back to its site of action again and again. That yields a half-life of roughly 22 hours, which carries the once-daily dose. An absolute bioavailability cannot formally be stated because ezetimibe does not dissolve in a vehicle suitable for injection, so the reference value is missing.

• Food: no relevant effect on absorption, take with or without a meal.
• CYP450: practically no contribution, hence a narrow interaction field.
• Onset: lipid effect builds over about two weeks, stable after roughly four weeks.

The meta-analysis by Pandor and colleagues across 2,722 participants showed an LDL reduction of roughly 19 percent versus placebo for monotherapy. That matches the corridor of about 15 to 20 percent commonly cited in the literature.

The actual core trial is IMPROVE-IT (Cannon et al., NEJM 2015). 18,144 patients after acute coronary syndrome, seven years of follow-up, simvastatin plus ezetimibe against simvastatin alone. LDL in the combination arm fell from 69.5 to 53.7 mg/dl, the combined cardiovascular endpoint from 34.7 to 32.7 percent. The absolute difference is small, the significance was large: it was the first major demonstration that additional LDL lowering with a non-statin on top of a statin delivers a measurable endpoint benefit.

SHARP (Baigent et al., Lancet 2011) found the same pattern in chronic kidney disease. EWTOPIA 75 (Ouchi et al., Circulation 2019) examined ezetimibe as monotherapy in primary prevention in people over 75.

Oral anabolics and AAS protocols shift the lipid profile in a documented unfavorable direction: HDL drops markedly, LDL rises. That is one of the best evidenced effects of this substance class and one of the few that shows up cleanly in blood work.

In that situation ezetimibe is the mildest available tool. No muscle compartment involved, no relevant hepatic CYP metabolism, a very flat side effect profile. Anyone already running a statin can place ezetimibe alongside it additively because the two mechanisms work independently.

The classification matters: the effect is moderate, not dramatic. Ezetimibe does not replace blood work, it is what makes blood work interpretable in the first place.

• Gastrointestinal: diarrhea, abdominal pain, flatulence - a direct consequence of the site of action in the small intestine, usually mild and early on.
• Fatigue: listed as an occasional effect, without a clear mechanism.
• Muscle complaints: at placebo level under monotherapy. The reported cases come almost exclusively from combination protocols with a statin.
• Liver values: transaminase elevations are documented, considerably more often in combination with a statin than under ezetimibe alone.
• Interactions: ciclosporin raises exposure markedly, fibrates moderately, bile acid sequestrants reduce uptake.

In the large endpoint trials the discontinuation rate due to adverse effects was not meaningfully above placebo. Ezetimibe is regarded as the best tolerated compound in its group.

Store dry, at room temperature and protected from light. Keep tablets in the original bottle and out of reach of children.